| Shelly Rivas, MD | |
|
3101 Shippers Rd Ste 102, Vestal, NY 13850-2081 | |
| (607) 251-2100 | |
| Not Available |
| Full Name | Shelly Rivas |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 11 Years |
| Location | 3101 Shippers Rd Ste 102, Vestal, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477999886 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 282663 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lourdes Hospital | Binghamton, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Our Lady Of Lourdes Memorial Hospital Inc | 1254237779 | 226 |
News Archive
The discovery of the UM171 molecule, by Dr. Guy Sauvageau and Anne Marinier, made headlines in 2014 following an article in Science. Hailed by some as a revolution, even a miracle, in the field of blood stem cell transplantation, the UM171 molecule is delivering on its promise.
Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.
One of the most recent and extensively studied determinants of fracture risk is trabecular bone score (TBS). TBS, which is assessed by lumbar spine dual-energy X-ray absorptiometry (DXA) imaging, provides information about the micro-architectural deterioration of bone tissue. Previous studies have shown that TBS predicts fracture in postmenopausal women and older men. TBS is currently used in conjunction with BMD values to enhance the predictive ability of the widely used Fracture Risk Assessment tool (FRAX), a calculator used to assess an individual's 10-year risk of major osteoporotic fracture.
About 19 percent of North Americans suffer from constipation, with the digestive condition being more common among women, non-whites, people older than 60, those who are not physically active and the poor.
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
› Verified 5 days ago
| Entity Name | Our Lady Of Lourdes Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629087580 PECOS PAC ID: 1254237779 Enrollment ID: O20031208000366 |
News Archive
The discovery of the UM171 molecule, by Dr. Guy Sauvageau and Anne Marinier, made headlines in 2014 following an article in Science. Hailed by some as a revolution, even a miracle, in the field of blood stem cell transplantation, the UM171 molecule is delivering on its promise.
Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.
One of the most recent and extensively studied determinants of fracture risk is trabecular bone score (TBS). TBS, which is assessed by lumbar spine dual-energy X-ray absorptiometry (DXA) imaging, provides information about the micro-architectural deterioration of bone tissue. Previous studies have shown that TBS predicts fracture in postmenopausal women and older men. TBS is currently used in conjunction with BMD values to enhance the predictive ability of the widely used Fracture Risk Assessment tool (FRAX), a calculator used to assess an individual's 10-year risk of major osteoporotic fracture.
About 19 percent of North Americans suffer from constipation, with the digestive condition being more common among women, non-whites, people older than 60, those who are not physically active and the poor.
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
› Verified 5 days ago
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
The discovery of the UM171 molecule, by Dr. Guy Sauvageau and Anne Marinier, made headlines in 2014 following an article in Science. Hailed by some as a revolution, even a miracle, in the field of blood stem cell transplantation, the UM171 molecule is delivering on its promise.
Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.
One of the most recent and extensively studied determinants of fracture risk is trabecular bone score (TBS). TBS, which is assessed by lumbar spine dual-energy X-ray absorptiometry (DXA) imaging, provides information about the micro-architectural deterioration of bone tissue. Previous studies have shown that TBS predicts fracture in postmenopausal women and older men. TBS is currently used in conjunction with BMD values to enhance the predictive ability of the widely used Fracture Risk Assessment tool (FRAX), a calculator used to assess an individual's 10-year risk of major osteoporotic fracture.
About 19 percent of North Americans suffer from constipation, with the digestive condition being more common among women, non-whites, people older than 60, those who are not physically active and the poor.
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shelly Rivas, MD 50 Front St Apt 323, Binghamton, NY 13905-4740 Ph: (917) 292-9316 | Shelly Rivas, MD 3101 Shippers Rd Ste 102, Vestal, NY 13850-2081 Ph: (607) 251-2100 |
News Archive
The discovery of the UM171 molecule, by Dr. Guy Sauvageau and Anne Marinier, made headlines in 2014 following an article in Science. Hailed by some as a revolution, even a miracle, in the field of blood stem cell transplantation, the UM171 molecule is delivering on its promise.
Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.
One of the most recent and extensively studied determinants of fracture risk is trabecular bone score (TBS). TBS, which is assessed by lumbar spine dual-energy X-ray absorptiometry (DXA) imaging, provides information about the micro-architectural deterioration of bone tissue. Previous studies have shown that TBS predicts fracture in postmenopausal women and older men. TBS is currently used in conjunction with BMD values to enhance the predictive ability of the widely used Fracture Risk Assessment tool (FRAX), a calculator used to assess an individual's 10-year risk of major osteoporotic fracture.
About 19 percent of North Americans suffer from constipation, with the digestive condition being more common among women, non-whites, people older than 60, those who are not physically active and the poor.
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
› Verified 5 days ago
Dr. Colleen Mary Crandell, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Plaza Dr, Suite B, Vestal, NY 13850 Phone: 607-729-2777 | |
Manisha Manmohan, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 | |
Romeo Morales, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 | |
Ayyaz M Shah, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 | |
Dr. Uzoma Oranu, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 | |
Dr. Genadij Sienkiewicz, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 200 Front St, Vestal, NY 13850 Phone: 607-658-1003 Fax: 607-658-1006 |